Precision oncology in gastric cancer: Shaping the future of personalized treatment
Cristina Migliore; Elisabetta Fenocchio; Silvia Giordano; Simona Corso · 2025 · Cancer Treatment Reviews
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract
Gastric cancer (GC) is the third leading cause of cancer-related mortality worldwide, and is associated with a very poor prognosis, largely due to its aggressive nature and, typically, late-stage diagnosis. Molecular classifications proposed one decade ago have provided valuable insights into the disease's heterogeneity and paved the way for clinical trials of tailored treatments. However, most of these trials have failed, often due to inadequate patient selection, lack of reliable biomarkers of response/resistance, or for the high level of inter- and intra-tumor heterogeneity characterizing t
Abstract by Cristina Migliore; Elisabetta Fenocchio; Silvia Giordano; Simona Corso, Cancer Treatment Reviews (2025) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Negative / Null Result ReportDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
Negative / Null Result ReportStenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis
Negative / Null Result ReportEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Replication FailureA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Negative / Null Result ReportSpironolactone for Heart Failure with Preserved Ejection Fraction
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.1016/j.ctrv.2025.103038